The global asbestosis treatment market size was valued at USD 1.94 billion in 2025 and is projected to grow from USD 2.05 billion in 2026 to USD 3.22 billion by 2034, registering a CAGR of 5.80% during the forecast period (2026-2034). North America dominated the asbestosis treatment market with a share of 42.10% in 2025.
Asbestosis treatment involves medical interventions to manage symptoms and improve respiratory function in patients with asbestos-related lung scarring. Medical devices include oxygen concentrators, nebulizers, and respiratory support equipment. These devices are classified under HSN Code 9019.20 (oxygen therapy and artificial respiration apparatus) and SIC Code 3841 (surgical and medical instruments and apparatus)
The asbestosis treatment market demand is driven by high healthcare expenditure and improved access to pulmonary care. The adoption of advanced oxygen therapy devices and expanding respiratory care services contribute to asbestosis treatment market growth.
Download a Free Sample To learn more about this report,
Preference for Home-Based Oxygen Therapy
The asbestosis treatment market analysis indicates preference for home-based oxygen therapy among patients with severe respiratory impairment. Portable oxygen concentrators support patient mobility and enable prescribed oxygen therapy outside hospitals. For example, Inogen's Rove 6 portable oxygen concentrator offers six pulse dose settings and up to 12 hours and 45 minutes of battery life.
Adoption of Pulmonary Telerehabilitation
Pulmonary telerehabilitation is gaining importance in the management of chronic respiratory diseases, including conditions requiring long-term respiratory support. Remote exercise supervision and patient education improve access to rehabilitation services for individuals with limited mobility. The American Thoracic Society recommends offering patients with chronic respiratory diseases a choice between center-based rehabilitation and telerehabilitation.
Supply chain disruptions are expected to have a moderate impact on the asbestosis treatment market share, mainly due to shortages of oxygen concentrators, respiratory equipment, and medical components. The market is expected to experience a K-shaped recovery as established medical device manufacturers maintain stable supplies through diversified sourcing. The market is projected to grow at a CAGR of 5.80%. Supply chain constraints could reduce short-term growth by 1.20 percentage points to 4.60%. Improved equipment availability and stable manufacturing operations are expected to support recovery toward 5.80%.
The asbestosis treatment market forecasts investment activity directed toward respiratory support technologies and pulmonary fibrosis research, supporting oxygen delivery innovation and the development of treatments for fibrotic lung diseases.
Key Investment and Funding Activities in Asbestosis Treatment Market, 2025–2026
Long Disease Latency and Need for Long-Term Respiratory Support Drive Market
The long latency period of asbestosis is sustaining demand for respiratory treatment among previously exposed workers. Symptoms often develop 20–40 years after asbestos exposure, creating treatment needs decades after occupational contact. The World Health Organization estimates that occupational asbestos exposure causes more than 200,000 deaths globally each year across asbestos related diseases. The continuing disease burden supports demand for oxygen therapy and long-term pulmonary care.
The progressive nature of asbestosis increases dependence on continuous medical care as lung function deteriorates. Patients with advanced disease may require supplemental oxygen to manage breathing difficulties. Regular pulmonary function assessments and respiratory monitoring also remain essential throughout treatment. The absence of curative treatment creates sustained demand for supportive care services and oxygen delivery equipment, particularly among patients experiencing severe respiratory impairment.
Absence of Curative Therapies and Limited Access to Specialized Pulmonary Rehabilitation Restrain Market Expansion
The absence of disease-reversing treatment remains a major restraint in the asbestosis treatment market. Existing therapies primarily manage breathing difficulties without removing established lung scarring. Oxygen therapy and pulmonary rehabilitation provide supportive benefits but cannot reverse asbestos-related fibrosis.
The limited availability of specialized pulmonary rehabilitation services restricts treatment access for asbestosis patients. Rehabilitation requires trained respiratory professionals and structured exercise supervision, which can be difficult to access outside major healthcare centers. Repeated hospital visits also create challenges for patients with reduced mobility.
AI-Assisted Lung Imaging and Development of Targeted Anti-Fibrotic Therapies Creates Growth Opportunities
Integration of artificial intelligence into lung imaging presents growth opportunities for the asbestosis treatment market. AI-assisted CT analysis helps identify asbestos-related lung fibrosis and supports accurate disease assessment. These capabilities create opportunities for diagnostic technology providers and specialized pulmonary care centers.
Development of targeted anti-fibrotic therapies presents opportunities for the asbestosis treatment market. Research into macrophage activity and cellular stress mechanisms could support treatments that slow asbestos-induced lung fibrosis. The U.S. National Institutes of Health is funding research into endoplasmic reticulum stress and its role in asbestos-related disease progression through May 2029. These developments create opportunities for disease-specific drug research, although effective targeted therapies remain investigational.
Symptomatic medication dominated the treatment type segment with a share of 34.60% in 2025 due to recurring prescriptions for cough relief and management of accompanying airway obstruction.
The pulmonary rehabilitation segment is estimated to register a growth rate of 6.70% during the forecast period, driven by the demand for supervised breathing exercises and physical conditioning. Structured rehabilitation programs improve exercise tolerance and help patients manage breathlessness.
Request Customizationto receive a tailored report.
In 2025, the moderate segment accounted for a share of 43.50% in 2025, owing to increasing treatment requirements among patients experiencing exertional breathlessness and measurable lung function decline. Regular pulmonary assessments and symptom management support continued healthcare utilization in this segment.
The severe segment will expand to 6.20% CAGR during the forecast period, as advanced pulmonary fibrosis increases dependence on supplemental oxygen. Greater risks of respiratory failure and pulmonary hypertension also increase demand for intensive respiratory care services.
The adults segment is estimated to reach 5.40% CAGR during the forecast period, driven by occupational asbestos exposure among construction and industrial workers.
Geriatric population segment is projected to reach at a CAGR of 6.10% during the forecast period, as prolonged disease latency increases diagnoses in older individuals. Age-related respiratory limitations and existing cardiopulmonary conditions increase the need for specialized treatment.
Hospitals led the healthcare setting segment with a share of 46.30% in 2025, owing to the availability of specialized pulmonologists and advanced respiratory treatment facilities. Hospital-based management of acute respiratory complications and severe hypoxemia supports higher utilization of inpatient care services.
The home care settings segment is likely to witness a CAGR of 6.80% during the forecast period, supported by the use of prescribed long-term oxygen therapy and preference for portable oxygen concentrators among caregivers.
Speak to an Analystto discuss market opportunities.
The North America asbestosis treatment market accounted for the largest regional share of 42.10% in 2025.
U.S. Asbestosis Treatment Market
The U.S. market is supported by continued diagnosis among people exposed to asbestos decades earlier and by persistent exposure risks in older buildings. EPA identifies legacy asbestos in buildings as a continuing health concern, especially during renovation and demolition. Medicare coverage for medically necessary home oxygen equipment also supports long-term respiratory management for eligible patients with reduced oxygen levels and chronic breathing impairment.
Canada Asbestosis Treatment Market
Health Canada states that asbestos may still remain in older buildings despite restrictions on new asbestos-containing products. Continued exposure risk during renovation and maintenance supports occupational monitoring, while established respiratory care services sustain treatment needs for patients who develop progressive breathing difficulty from past exposure.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific asbestosis treatment market is expected to grow at a CAGR of 6.20% during the forecast period, showcasing the fastest-growing regional market.
China Asbestosis Treatment Market
National Health Commission reports that 900 pneumoconiosis rehabilitation stations have provided more than two million free rehabilitation visits. National respiratory disease policy also promotes pulmonary function assessment, exercise rehabilitation, and community-based management, strengthening access to supportive care for patients with chronic dust-related respiratory disease.
India Asbestosis Treatment Market
India is shaped by occupational health surveillance in asbestos product industries and access to specialized respiratory testing. DGFASLI’s Industrial Medicine Division conducts health surveys in asbestos manufacturing and maintains facilities for ILO radiography and pulmonary function testing. These services can improve identification of occupational lung damage, while clinical follow-up and respiratory support remain important for workers with irreversible fibrosis and breathing impairment.
Japan Asbestosis Treatment Market
Japan's market is propelled by a national asbestos health damage relief system that covers severe asbestosis with respiratory dysfunction. Certified patients can receive medical expense support and monthly medical care allowances, reducing the financial burden of prolonged treatment. Japan also maintains formal application and medical assessment pathways for asbestos-related disease, supporting continued identification and care of patients affected by historical occupational and environmental exposure.
The Europe asbestosis treatment market is expected to experience a growth rate of 5.10% during the forecast period.
UK Asbestosis Treatment Market
UK has an established occupational disease surveillance framework that helps identify affected workers and supports clinical follow-up. Access to respiratory specialists, pulmonary rehabilitation, oxygen therapy, and long-term symptom management continues to sustain treatment demand among patients with progressive asbestos-related lung fibrosis.
Germany Asbestosis Treatment Market
Statutory accident insurance provides a structured pathway for diagnosis, medical care, and rehabilitation of affected workers. Germany’s established pulmonary care infrastructure also supports long-term disease management, while the extended latency of asbestos-related lung damage continues to generate treatment needs among previously exposed industrial and construction workers.
The Latin America asbestosis treatment market is anticipated to record a growth rate of 5.90% during the forecast period. Brazil’s RENAST network provides specialized worker-health services through CEREST centers, supporting diagnosis, treatment, and rehabilitation for occupational diseases across a broad municipal network.
Mexico maintains specific medical surveillance requirements for asbestos-exposed workers. The national standard requires annual health examinations and includes chest radiography and spirometry, helping identify respiratory impairment and supporting continued clinical management of affected workers.
The Middle East & Africa asbestosis treatment market is estimated to grow at a CAGR of 6.20% during the forecast period. The UAE maintains specific asbestos handling requirements through Dubai Municipality and formal standards for occupational health services, supporting exposure assessment and referral of workers requiring respiratory evaluation.
South Africa provides structured medical support for occupational lung diseases through the Compensation Commissioner for Occupational Diseases. Eligible mineworkers can receive free benefit medical examinations every two years, while occupational disease compensation mechanisms support medical care and rehabilitation.
The asbestosis treatment market competitive landscape is moderately fragmented, comprising respiratory medical device manufacturers, oxygen therapy providers, specialized healthcare institutions, and regional rehabilitation centers. Key players such as Inogen, CAIRE, Drive DeVilbiss Healthcare, Linde, AdaptHealth, and React Health are estimated to account for over 35% of the global asbestosis treatment market share.
Established companies compete through oxygen delivery technology, extensive distribution networks, and treatment accessibility. Regional providers in the asbestosis treatment market ecosystem focus on affordable respiratory support, specialized pulmonary rehabilitation, and personalized patient care.
September 2026: Inogen signed an agreement to sell its U.S. oxygen rental business to Rotech Healthcare for up to USD 25 million, alongside a long-term oxygen concentrator supply agreement.
August 2026: Inogen announced the launch of its Rove 6 portable oxygen concentrator in Canada, expanding access to oxygen therapy equipment for patients with chronic respiratory conditions.
July 2026: Philips received U.S. FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, designed to improve oxygen saturation measurement accuracy.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Brain Tumor Treatment Market Size, Forecast, Demand, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Medical Aesthetics Market Size, Share, Growth, Analysis, 2034
Byler Disease Market Size, Forecast, Demand, Opportunities, 2034
Complement Inhibitors Market Size, Share, Growth, Analysis, 2034
Antidiabetics Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com